Meeting Overview - The fourth supervisory board meeting of Jia Bi You Biotechnology (Wuhan) Co., Ltd. was held on June 9, 2025, with all three supervisors present [1] - The meeting was convened and chaired by Wang Ji, ensuring compliance with relevant laws and regulations [1] Resolutions Passed - The supervisory board approved the adjustment of the asset acquisition and fundraising plan, which involves issuing shares and cash to purchase Shanghai Ouyi Biomedical Technology Co., Ltd. The adjustment includes changes to the performance compensation calculation method and the addition of impairment compensation clauses [1][2] - The board also approved the revised draft of the asset acquisition report and its summary, ensuring compliance with the Securities Law and relevant regulations [2][3] - A supplementary agreement regarding the asset acquisition agreement with certain counterparties was approved [3] - A supplementary agreement concerning performance compensation commitments was also approved [4] - The board confirmed that the transaction complies with the relevant provisions of the Major Asset Restructuring Management Measures [4][5] - The board affirmed that the transaction meets the regulatory requirements for major asset restructuring [4][5] - The board determined that there are no circumstances that would prevent the company from issuing shares to specific targets [5] - The board approved the pro forma financial statements related to the transaction and their review report [5] - Measures to mitigate the dilution of immediate returns from the transaction were also approved [5]
嘉必优: 嘉必优生物技术(武汉)股份有限公司第四届监事会第六次会议决议公告